SCM
FATE icon

Segantii Capital Management’s Fate Therapeutics FATE Stock Holding History

Segantii Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-39,999
Closed -$182K – 122
2017
Q1 		$182K Buy
+39,999
New +$146K 0.03% 153

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Segantii Capital Management's FATE Position: Q2 2017 in Review

Segantii Capital Management sold out of Fate Therapeutics (FATE) in Q2 2017, closing a stake of 39,999 shares — an estimated $182K sold.

Segantii Capital Management first reported a position in FATE in Q1 2017 and held it in 1 quarter. The position peaked at $182K in Q1 2017. 60 funds tracked by Wall St. Rank hold FATE as of Q2 2017.

  • Segantii Capital Management reported no remaining Fate Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 39,999 Fate Therapeutics shares in Q2 2017, an estimated $182K.
  • Segantii Capital Management first reported a position in Fate Therapeutics in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Fate Therapeutics position peaked at $182K in Q1 2017.
  • 60 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.